Jason Bydash, DO
Nephrology · Eau Claire, WINPI 1669628632
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,315 of the $4,801 with a category attached, or 69.0%. Baxter Healthcare accounts for 93.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $4,631 and has fallen 99.2% since, to $35 in 2024.
Across 19 payments — averaging $252.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$5K
- Calliditas Therapeutics US Inc.$87
- Medtronic$65
- Novartis$65
- Otsuka America Pharmaceutical, Inc.$61
- Vifor Pharma, Inc.$17
What the payments were for
- Consulting fees$3,31569%
- Travel & lodging$1,00821%
- Food & beverage$4038%
- Education$752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 10 | $4,505 |
| Calliditas Therapeutics US Inc. | 5 | $87 |
| Medtronic | 1 | $65 |
| Novartis | 1 | $65 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Vifor Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - HD$4,323
How this compares
$4,801 in reported general payments places this provider in the 85th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 129 | $95,211 |
| JardianceEmpagliflozin | 48 | $56,053 |
| OzempicSemaglutide | 30 | $31,391 |
| EliquisApixaban | 28 | $24,382 |
| KerendiaFinerenone | 27 | $18,910 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $12,195 |
| Calcitriol | 202 | $3,637 |
| Potassium Citrate ErPotassium Citrate | 20 | $3,353 |
| Calcium Acetate | 38 | $2,797 |
| Nifedipine ErNifedipine | 87 | $2,595 |
| Losartan Potassium | 273 | $2,385 |
| Metoprolol Succinate | 102 | $1,668 |
| Torsemide | 84 | $1,484 |
| Famotidine | 83 | $1,382 |
| Prazosin Hcl | 18 | $1,255 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Eau Claire
- Kevin RegnerMilwaukee$246K
- Rosanna RanieriKenosha$84K
- Micah ChanFitchburg$80K
- Rishi KoraGlendale$57K
- Manohar AhujaMilwaukee$35K
- Ashraf El MeanawyMilwaukee$30K
- Anna GaddyMilwaukee$28K
- Sameer GuptaFond du Lac$20K
- Paul HannaMilwaukee$18K
- Fahad AzizFitchburg$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.